Amgen — Oct 30, 2024 release

pts: percentage points N/A = not applicable Cash Flow and Balance Sheet • The Company generated $3.3 billion of free cash flow in the third quarter of 2024 versus $2.5 billion in the third quarter of 2023, driven by business performance and timing of working capital items, partially offset by lower interest income. • The Company’s third quarter 2024 dividend of $2.25 per share was declared on August 2, 2024, and was paid on September 6, 2024, to all stockholders of record as of August 16, 2024, representing a 6% increase from this same period in 2023. • During the third quarter, the Company reduced principal debt outstanding by $2.5 billion. Year-to-date, the Company has reduced principal debt outstanding by $4.5 billion. • Cash and investments totaled $9.0 billion and debt outstanding totaled $60.4 billion as of September 30, 2024. $Billions, except shares Q3 ’24 Q3 ’23 YOY Δ Operating Cash Flow $ 3.6  $ 2.8  $ 0.8  Capital Expenditures $ 0.3  $ 0.2  $ 0.0  Free Cash Flow $ 3.3  $ 2.5  $ 0.8  Dividends Paid $ 1.2  $ 1.1  $ 0.1  Share Repurchases $ 0.0  $ —  $ 0.0  Average Diluted Shares (millions) 542  538  4  Note: Numbers may not add due to rounding $Billions 9/30/24 12/31/23 YTD Δ Cash and Investments $ 9.0  $ 10.9  $ (1.9) Debt Outstanding $ 60.4  $ 64.6  $ (4.2) Note: Numbers may not add due to rounding AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Page 7 2024 Guidance For the full year 2024, the Company now expects: • Total revenues in the range of $33.0 billion to $33.8 billion. • On a GAAP basis, EPS in the range of $8.71 to $9.56, and a t